Laurion Capital Management LP cut its stake in shares of Cellectis SA (NASDAQ:CLLS) by 32.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 134,700 shares of the biotechnology company’s stock after selling 65,300 shares during the period. Laurion Capital Management LP owned 0.32% of Cellectis worth $3,801,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Cellectis in the third quarter valued at approximately $129,000. Commonwealth Equity Services LLC acquired a new stake in shares of Cellectis in the second quarter valued at approximately $237,000. Prosight Management LP acquired a new stake in shares of Cellectis in the second quarter valued at approximately $548,000. Adalta Capital Management LLC acquired a new stake in shares of Cellectis in the second quarter valued at approximately $620,000. Finally, OLD Mission Capital LLC lifted its position in shares of Cellectis by 266.0% in the second quarter. OLD Mission Capital LLC now owns 27,768 shares of the biotechnology company’s stock valued at $786,000 after buying an additional 20,182 shares during the last quarter. 27.68% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have recently issued reports on the company. Zacks Investment Research raised Cellectis from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Friday, November 16th. ValuEngine raised Cellectis from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. BidaskClub cut Cellectis from a “sell” rating to a “strong sell” rating in a research report on Wednesday, November 21st. Finally, Oppenheimer set a $44.00 price objective on Cellectis and gave the company a “buy” rating in a research report on Sunday, November 25th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $48.00.
Shares of NASDAQ CLLS opened at $20.25 on Friday. The company has a market cap of $858.32 million, a PE ratio of -7.28 and a beta of 1.71. Cellectis SA has a 1-year low of $20.15 and a 1-year high of $38.85.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/12/08/laurion-capital-management-lp-sells-65300-shares-of-cellectis-sa-clls.html.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Featured Story: How to Invest in the Dividend Aristocrat Index
Want to see what other hedge funds are holding CLLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectis SA (NASDAQ:CLLS).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.